McCarver Gail, Bhatia Jatinder, Chambers Christina, Clarke Robert, Etzel Ruth, Foster Warren, Hoyer Patricia, Leeder J Steven, Peters Jeffrey M, Rissman Emilie, Rybak Michael, Sherman Claire, Toppari Jorma, Turner Katie
Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Birth Defects Res B Dev Reprod Toxicol. 2011 Oct;92(5):421-68. doi: 10.1002/bdrb.20314. Epub 2011 Sep 21.
Soy infant formula contains soy protein isolates and is fed to infants as a supplement to or replacement for human milk or cow milk. Soy protein isolates contains estrogenic isoflavones (phytoestrogens) that occur naturally in some legumes, especially soybeans. Phytoestrogens are nonsteroidal, estrogenic compounds. In plants, nearly all phytoestrogens are bound to sugar molecules and these phytoestrogen-sugar complexes are not generally considered hormonally active. Phytoestrogens are found in many food products in addition to soy infant formula, especially soy-based foods such as tofu, soy milk, and in some over-the-counter dietary supplements. Soy infant formula was selected for National Toxicology Program (NTP) evaluation because of (1) the availability of large number of developmental toxicity studies in laboratory animals exposed to the isoflavones found in soy infant formula (namely, genistein) or other soy products, as well as few studies on human infants fed soy infant formula, (2) the availability of information on exposures in infants fed soy infant formula, and (3) public concern for effects on infant or child development. On October 2, 2008 (73 FR 57360), the NTP Center for the Evaluation of Risks to Human Reproduction (CERHR) announced its intention to conduct an updated review of soy infant formula to complete a previous evaluation that was initiated in 2005. Both the current and previous evaluations relied on expert panels to assist the NTP in developing its conclusions on the potential developmental effects associated with the use of soy infant formula, presented in the NTP Brief on Soy Infant Formula. The initial expert panel met on March 15 to 17, 2006, to reach conclusions on the potential developmental and reproductive toxicities of soy infant formula and its predominant isoflavone constituent genistein. The expert panel reports were released for public comment on May 5, 2006 (71 FR 28368). On November 8, 2006 (71 FR 65537), CERHR staff released draft NTP Briefs on Genistein and Soy Formula that provided the NTP's interpretation of the potential for genistein and soy infant formula to cause adverse reproductive and/or developmental effects in exposed humans. However, CERHR did not complete these evaluations, finalize the briefs, or issue NTP Monographs on these substances based on this initial evaluation. Between 2006 and 2009, a substantial number of new publications related to human exposure or reproductive and/or developmental toxicity were published for these substances. Thus, CERHR determined that updated evaluations of genistein and soy infant formula were needed. However, the current evaluation focuses only on soy infant formula and the potential developmental toxicity of its major isoflavone components, e.g. genistein, daidzein (and estrogenic metabolite, equol), and glycitein. This updated evaluation does not include an assessment on the potential reproductive toxicity of genistein following exposures during adulthood as was carried out in the 2006 evaluation. CERHR narrowed the scope of the evaluation because the assessment of reproductive effects of genistein following exposure to adults was not considered relevant to the consideration of soy infant formula use in infants during the 2006 evaluation. To obtain updated information about soy infant formula for the CERHR evaluation, the PubMed (Medline) database was searched from February 2006 to August 2009 with genistein/genistin, daidzein/daidzin, glycitein/glycitin, equol, soy, and other relevant keywords. References were also identified from the bibliographies of published literature. The updated expert panel report represents the efforts of a 14-member panel of government and nongovernment scientists, and was prepared with assistance from NTP staff. The finalized report, released on January 15, 2010 (75 FR 2545), reflects consideration of public comments received on a draft report that was released on October 19, 2009, for public comment and discussions that occurred at a public meeting of the expert panel held December 16 to 18, 2009 (74 FR 53509). The finalized report presents conclusions on (1) the strength of scientific evidence that soy infant formula or its isoflavone constituents are developmental toxicants based on data from in vitro, animal, or human studies; (2) the extent of exposures in infants fed soy infant formula; (3) the assessment of the scientific evidence that adverse developmental health effects may be associated with such exposures; and (4) knowledge gaps that will help establish research and testing priorities to reduce uncertainties and increase confidence in future evaluations. The Expert Panel expressed minimal concern for adverse developmental effects in infants fed soy infant formula. This level of concern represents a "2" on the five-level scale of concern used by the NTP that ranges from negligible concern ("1") to serious concern ("5"). The Expert Panel Report on Soy Infant Formula was considered extensively by NTP staff in preparing the 2010 NTP Brief on Soy Infant Formula, which represents the NTP's opinion on the potential for exposure to soy infant formula to cause adverse developmental effects in humans. The NTP concurred with the expert panel that there is minimal concern for adverse effects on development in infants who consume soy infant formula. This conclusion was based on information about soy infant formula provided in the expert panel report, public comments received during the course of the expert panel evaluation, additional scientific information made available since the expert panel meeting, and peer reviewer critiques of the draft NTP Brief by the NTP Board of Scientific Counselors (BSC) on May 10, 2010 (Meeting materials are available at http://ntp.niehs.nih.gov/go/9741.). The BSC voted in favor of the minimal concern conclusion with 7 yes votes, 3 no votes, and 0 abstentions. One member thought that the conclusion should be negligible concern and two members thought that the level of concern should be higher than minimal concern. The NTP's response to the May 10, 2010 review ("peer-review report") is available on the NTP website at http://ntp.niehs.nih.gov/go/9741. The monograph includes the NTP Brief on Soy Infant Formula as well as the entire final Expert Panel Report on Soy Infant Formula. Public comments received as part of the NTP's evaluation of soy infant formula and other background materials are available at http://cerhr.niehs.nih.gov/evals/index.html.
大豆婴儿配方奶粉含有大豆分离蛋白,作为母乳或牛奶的补充品或替代品喂给婴儿。大豆分离蛋白含有雌激素异黄酮(植物雌激素),这些物质天然存在于一些豆类中,尤其是大豆。植物雌激素是一类非甾体类的雌激素化合物。在植物中,几乎所有的植物雌激素都与糖分子结合,这些植物雌激素 - 糖复合物通常不被认为具有激素活性。除了大豆婴儿配方奶粉外,许多食品中都含有植物雌激素,特别是大豆类食品,如豆腐、豆浆,以及一些非处方膳食补充剂。选择大豆婴儿配方奶粉进行国家毒理学计划(NTP)评估的原因如下:(1)有大量关于实验室动物暴露于大豆婴儿配方奶粉(即染料木黄酮)或其他大豆制品中所含异黄酮的发育毒性研究,而关于食用大豆婴儿配方奶粉的人类婴儿的研究较少;(2)有关于食用大豆婴儿配方奶粉的婴儿的暴露信息;(3)公众对其对婴儿或儿童发育的影响表示关注。2008年10月2日(73 FR 57360),NTP人类生殖风险评估中心(CERHR)宣布打算对大豆婴儿配方奶粉进行更新审查,以完成2005年开始的先前评估。当前和先前的评估都依靠专家小组协助NTP得出关于使用大豆婴儿配方奶粉可能产生的发育影响的结论,这些结论在NTP关于大豆婴儿配方奶粉的简报中有所呈现。最初的专家小组于2006年3月15日至17日召开会议,就大豆婴儿配方奶粉及其主要异黄酮成分染料木黄酮的潜在发育和生殖毒性得出结论。专家小组报告于2006年5月5日发布供公众评论(71 FR 28368)。2006年11月8日(71 FR 65537),CERHR工作人员发布了关于染料木黄酮和大豆配方奶粉的NTP简报草案,其中提供了NTP对染料木黄酮和大豆婴儿配方奶粉在暴露人群中导致不良生殖和/或发育影响可能性的解读。然而,CERHR并未完成这些评估,敲定简报,也未基于这一初步评估发布关于这些物质的NTP专论。2006年至2009年期间,发表了大量与这些物质的人体暴露或生殖和/或发育毒性相关的新出版物。因此,CERHR确定需要对染料木黄酮和大豆婴儿配方奶粉进行更新评估。然而,当前评估仅关注大豆婴儿配方奶粉及其主要异黄酮成分(如染料木黄酮、黄豆苷元(及其雌激素代谢物雌马酚)和大豆黄素)的潜在发育毒性。此次更新评估不包括如2006年评估那样对成年期暴露后染料木黄酮的潜在生殖毒性进行评估。CERHR缩小了评估范围,因为在2006年评估中,染料木黄酮暴露于成年人后的生殖影响评估被认为与考虑婴儿食用大豆婴儿配方奶粉无关。为了获取用于CERHR评估的关于大豆婴儿配方奶粉的更新信息,在2006年2月至2009年8月期间使用染料木黄酮/染料木苷、黄豆苷元/黄豆苷、大豆黄素/大豆黄苷、雌马酚、大豆及其他相关关键词对PubMed(Medline)数据库进行了搜索。还从已发表文献的参考文献中识别出相关文献。更新后的专家小组报告代表了一个由14名政府和非政府科学家组成的小组的努力,并在NTP工作人员的协助下编写而成。最终报告于2010年1月15日发布(75 FR 2545),反映了对2009年10月19日发布供公众评论的报告草案所收到的公众意见的考虑,以及2009年12月16日至18日专家小组公开会议上进行的讨论(74 FR 53509)。最终报告得出了以下结论:(1)基于体外、动物或人体研究数据,大豆婴儿配方奶粉或其异黄酮成分作为发育毒物的科学证据的强度;(2)食用大豆婴儿配方奶粉的婴儿的暴露程度;(3)关于此类暴露可能与不良发育健康影响相关的科学证据的评估;(4)有助于确定研究和测试重点以减少不确定性并增强未来评估信心的知识空白。专家小组对食用大豆婴儿配方奶粉的婴儿的不良发育影响表示极少关注。这种关注程度在NTP使用的从可忽略关注(“1”)到严重关注(“5”)的五级关注量表中代表“2”。NTP工作人员在编写2010年NTP关于大豆婴儿配方奶粉的简报时广泛考虑了大豆婴儿配方奶粉专家小组报告,该简报代表了NTP对接触大豆婴儿配方奶粉可能对人类造成不良发育影响的可能性的意见。NTP同意专家小组的观点,即对食用大豆婴儿配方奶粉的婴儿的发育影响极少关注。这一结论基于专家小组报告中提供的关于大豆婴儿配方奶粉的信息、专家小组评估过程中收到的公众意见、专家小组会议后提供的额外科学信息,以及NTP科学顾问委员会(BSC)于2010年5月10日对NTP简报草案的同行评审批评(会议材料可在http://ntp.niehs.nih.gov/go/9741获取)。BSC以7票赞成、3票反对、0票弃权的投票结果支持极少关注的结论。一名成员认为结论应为可忽略关注,两名成员认为关注程度应高于极少关注。NTP对2010年5月10日审查(“同行评审报告”)的回应可在NTP网站http://ntp.niehs.nih.gov/go/9741上获取。该专论包括NTP关于大豆婴儿配方奶粉的简报以及整个最终的大豆婴儿配方奶粉专家小组报告。作为NTP对大豆婴儿配方奶粉评估一部分收到的公众意见及其他背景材料可在http://cerhr.niehs.nih.gov/evals/index.html获取。